Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Alexander Annala
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
City of Hope
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
1. Therabiologics, Inc. is a clinical-stage biopharmaceutical company developing human neural stem cell (NSC)-mediated cancer therapies. TheraBiologics’ TBX.NSC platform has been engineered to deliver a diverse range of potent anti-cancer agents selectively to invasive cancer sites in order to maximize therapeutic concentrations at the disease target and minimize off target toxicities. Dr. Annala is Key Personnel on the funded research grant regarding the identification of the optimal dose and scheduling of carboxylesterase (CE)-secreting neural stem cells in combination with Irinotecan (CPT11) for a tumor selective, more effective treatment of high-risk neuroblastoma. Given the similarities between the company’s product development and the aims of the grant, the interest was determined to be related.
2. Therabiologics, Inc. is a clinical-stage biopharmaceutical company developing human neural stem cell (NSC)-mediated cancer therapies. TheraBiologics’ TBX.NSC platform has been engineered to deliver a diverse range of potent anti-cancer agents selectively to invasive cancer sites in order to maximize therapeutic concentrations at the disease target and minimize off target toxicities. Dr. Annala is Key Personnel on the funded research grant regarding the identification of the optimal dose and scheduling of carboxylesterase (CE)-secreting neural stem cells in combination with Irinotecan (CPT11) for a tumor selective, more effective treatment of high-risk neuroblastoma. Given the similarities between the company’s product development and the aims of the grant, the interest was determined to be related.
Neural Stem Cell Mediated CE-CPT11 Therapy for Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor of childhood, with 45% of these patients diagnosed with metastatic high-risk tumors and having limited treatment options. Neural stem cells (NSCs) can home to invasive cancer sites, which make them a promising delivery vehicle for therapeutic agents. The goal of this U-01 proposal is to identify the optimal dose and schedule of enzyme-secreting NSCs that will convert the prodrug CPT-11 (Irinotecan) to the potent anti-cancer agent SN-38 locally at the tumor sites -potentially providing a tumor selective, more effective and less toxic treatment for children with high-risk neuoblastoma. NOTE: The critiques and criterion scores from individual reviewers are provided below in an essentially unedited form. The Resume and Summary of Discussion above summarizes the final outcome of the group discussion.
Filed on October 21, 2013.
Tell us what you know about Alexander Annala's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Alexander Annala”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Alexander Annala | Beckman Research Institute/city of Hope | Conflict of Interest | City of Hope | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.